Top

The European Journal of Health Economics

Published in:

01-06-2007 | Discussion

Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi

Author: Joshua Cohen

Published in: The European Journal of Health Economics | Issue 2/2007

Excerpt

In their editorial, Garattini and Ghislandi (GG) suggest we should not necessarily worry about non-launches and launch delays of new chemical entities (NCEs) that could be attributed to price controls [1]. GG direct their comments at Danzon et al. [2]. …

Garatinni, L., Ghislandi, S.: Should we really worry about “launch delays” of new drugs in OECD countries?” Eur. J. Health Econ. 8, 1–3 (2007)CrossRef

Danzon, P., Wang, M., Wang, L.: The impact of price regulation on the launch delay of new drugs—evidence from twenty five major markets in the 1990s. Health Econ. 14, 269–295 (2005)CrossRef

Cohen, J., Faden, L., Predaris, S., Young, B.: Patient access to pharmaceuticals: an international comparison. Eur. J. Health Econ. (2007) http://dx.doi.org/10.1007/s10198-006-0028-z

Devlin, N., Parkin, D.: Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 13(5), 437–452 (2004)CrossRef

Jonsson, B., Wilking, N.: A pan-European comparison of patient access to cancer medications. See http://ki.se/content/1/c4/33/52/Cancer_Report.pdf. Accessed 11 March (2007)

Title: Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi
Author: Joshua Cohen
Publication date: 01-06-2007
Publisher: Springer-Verlag
Published in: The European Journal of Health Economics / Issue 2/2007
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-007-0055-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2007

The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management

The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience

Discussion point: should governments buy drug patents?

The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen